How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

The US-China race for artificial intelligence dominance has entered a new phase: using AI to build better AI. Leading AI companies in the United States and China are increasingly focused on deploying ...

Two solid-value approaches, one well-built ETF. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform their Morningstar Category average over a market ...

Public health in the region faces new challenges such as the reemergence of infectious diseases and changes in political, social and economic aspects that determine the health and health equity of the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Solid-state battery specialist Factorial Energy is teaming up with Mitsui Kinzoku, one of the few companies producing sulfide-based solid electrolytes, to scale up the promising new technology.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...